This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

H. N. COLE, M.D.; R. B. PALMER, M.D.

Arch Derm Syphilol. 1937;36(3):561-580.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The trivalent arsenical preparation meta-aminoparahydroxyphenylarsine oxide was studied originally by Ehrlich and Bertheim and later by Voegtlin and others. Ehrlich and Hata¹ found its therapeutic index to be less than that of the arsphenamines. Voegtlin² considered arsenoxide for clinical use in the treatment of syphilis but hesitated because its margin of safety as established by the chemotherapeutic index appeared to be somewhat lower than that of arsphenamine. The attention of chemotherapeutists was again called to arsenoxide as the result of the experiments of Tatum and Cooper.³ These investigators found that the therapeutic index and other properties were such as to make the drug more promising than any other single antisyphilitic agent. Gruhzit,⁴ in studies on experimental trypanosomiasis and syphilis, found that arsenoxide was well tolerated and possessed a therapeutic value at least as high as that of neoarsphenamine.

Mapharsen is meta-aminoparahydroxyphenylarsine oxide hydrochloride, generally known by . . . [Full Text PDF of this Article]

Author Affiliations
CLEVELAND; LINCOLN, NEB.

From the Departments of Dermatology and Syphilology of the Western Reserve University School of Medicine and of the University Hospital and the City Hospital, Cleveland.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?